title: Myocardial viability in chronic ischemic heart disease: comparison of delayed-enhancement magnetic resonance imaging with 99mTc-sestamibi and 18F-fluorodeoxyglucose single-photon emission computed tomography.
abstract: OBJECTIVE
  We sought to compare delayed-enhancement MRI (DE-MRI) with 99mTc-sestamibi and 18F-fluorodeoxyglucose (18F-FDG) single-photon emission computed tomography (SPECT) for the assessment of myocardial viability.
  
  
  METHODS
  Thirty-four patients with prior myocardial infarction underwent DE-MRI and 99mTc-sestamibi/18F-FDG SPECT. The area of delayed enhancement by DE-MRI was defined as scar tissue. The region with concordantly reduced perfusion and glucose metabolism was defined as nonviable myocardium. In a 17-segment model, the segmental extent of hyperenhancement was compared with segmental 99mTc-sestamibi and 18F-FDG uptake defect. All segments were divided into five different severities by segmental extent of hyperenhancement in DE-MRI and were classified into different viability situations by segmental 99mTc-sestamibi and 18F-FDG uptake in SPECT.
  
  
  RESULTS
  A total of 578 segments were studied. Sensitivity and specificity of DE-MRI in identifying segments with flow/metabolism match were 61.32 and 95.35%, respectively. Semiquantitatively assessed relative MRI scar tissue correlated well with 99mTc-sestamibi and 18F-FDG SPECT (r = 0.63, P = 0.0284). However, of the 431 segments defined as normal by DE-MRI, 82 segments (19%) were scored as nonviable by 18F-FDG SPECT. During these segments, 48 showed less than 50% reduced 18F-FDG uptake, 25 showed 50-75% reduced 18F-FDG uptake, and nine showed no 18F-FDG uptake.
  
  
  CONCLUSIONS
  MRI hyperenhancement as a marker of myocardial scar closely agrees with 99mTc-sestamibi and 18F-FDG SPECT. Nuclear technology and DE-MRI show their own predominance and limitation in assessment of myocardial viability and detecting irreversibly injured tissue.
authors.affiliation: Department of Radiology, Cardiovascular Institute and Fuwai Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China.
authors.forename: Qiong
authors.initials: Q
authors.lastname: Liu
authors.forename: Shihua
authors.initials: S
authors.lastname: Zhao
authors.forename: Chaowu
authors.initials: C
authors.lastname: Yan
authors.forename: Minjie
authors.initials: M
authors.lastname: Lu
authors.forename: Shiliang
authors.initials: S
authors.lastname: Jiang
authors.forename: Yan
authors.initials: Y
authors.lastname: Zhang
authors.forename: Shiguo
authors.initials: S
authors.lastname: Li
authors.forename: Yuqing
authors.initials: Y
authors.lastname: Liu
authors.forename: Minfu
authors.initials: M
authors.lastname: Yang
authors.forename: Zuoxiang
authors.initials: Z
authors.lastname: He
mesh_terms: D002908:Chronic Disease; D002921:Cicatrix / Q000000981:diagnostic imaging / Q000473:pathology; D005260:Female; D019788:Fluorodeoxyglucose F18; D006321:Heart / Q000000981:diagnostic imaging / Q000503:physiopathology*; D006801:Humans; D008279:Magnetic Resonance Imaging; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000175:diagnosis* / Q000000981:diagnostic imaging / Q000503:physiopathology*; D017256:Technetium Tc 99m Sestamibi; D013997:Time Factors; D014022:Tissue Survival; D015899:Tomography, Emission-Computed, Single-Photon
chemical_list: D019788:Fluorodeoxyglucose F18; D017256:Technetium Tc 99m Sestamibi